News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BMEYE Announces CE Mark Approval of Nexfin(TM)


7/23/2007 8:46:30 AM

AMSTERDAM, July 23 /PRNewswire/ -- BMEYE(TM) announced today CE Mark approval of Nexfin(TM), their newly developed line of accurate and easy to use hemodynamic monitors. The Nexfin(TM) monitors provide accurate and easy to use continuous non-invasive blood pressure and cardiac output monitoring.

"BMEYE(TM) was established to develop and market innovative technology that will transform the practice of medicine in hemodynamic patient monitoring. We are pleased and gratified by the CE Mark approval enabling us to market the Nexfin(TM) to cardiologists and any clinician who needs to measure continuous non-invasive blood pressure and cardiac output easily and accurately", said Bill Bednarski, CEO of BMEYE(TM). "The Nexfin(TM) is cost effective and will significantly improve patient care."

BMEYE(TM), based in Amsterdam and St. Louis, develops and markets innovative medical technology with broad applications in a variety of clinical settings. The focus of BMEYE(TM) is on accurate and easy to use non-invasive hemodynamic monitoring. The Nexfin(TM) family of monitors use an easy to apply finger sensor to produce accurate continuous non-invasive blood pressure and cardiac output data displayed on an intuitive touchscreen.

Patents pending. For more information please check our web site at www.bmeye.com.

BMEYE

CONTACT: Contact Information: Bill Bednarski, CEO BMEYE, Academic MedicalCenter, Suite K2-245, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands,Phone: +31-(0)20-566-7720, Email: bill.bednarski@bmeye.com; Center forEmerging Technologies, 4041 Forest Park Avenue, St. Louis, Missouri, 63108,USA, Phone: +1-(925)270-0741


Read at BioSpace.com


comments powered by Disqus
BMEYE
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES